Cargando…

Enhanced recovery after surgery (ERAS) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a cross-sectional survey

OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols have been questioned in patients undergoing cytoreductive surgery (CRS) with/without hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies. This survey was performed to study clinicians’ practice about ERAS in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhandoria, Geetu, Solanki, Sohan Lal, Bhavsar, Mrugank, Balakrishnan, Kalpana, Bapuji, Cherukuri, Bhorkar, Nitin, Bhandarkar, Prashant, Bhosale, Sameer, Divatia, Jigeeshu V., Ghosh, Anik, Mahajan, Vikas, Peedicayil, Abraham, Nath, Praveen, Sinukumar, Snita, Thambudorai, Robin, Seshadri, Ramakrishnan Ayloor, Bhatt, Aditi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482448/ https://www.ncbi.nlm.nih.gov/pubmed/34676283 http://dx.doi.org/10.1515/pp-2021-0117

Ejemplares similares

The use of Hypotension Prediction Index in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Gangakhedkar, Gauri R., et al.
Publicado: (2022)

Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Solanki, Sohan Lal, et al.
Publicado: (2019)

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
por: Vassos, Nikolaos, et al.
Publicado: (2016)

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
por: Pamela, Kogler, et al.
Publicado: (2018)

Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center
por: Račkauskas, Rokas, et al.
Publicado: (2022)

The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Tan, Grace Hwei Ching, et al.
Publicado: (2018)

Cytoreductive Surgery (CRS) and Hyperthermic IntraPeritoneal Chemotherapy (HIPEC): don’t throw the baby out with the bathwater
por: Königsrainer, Alfred, et al.
Publicado: (2018)

Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Chokshi, Ravi J., et al.
Publicado: (2020)

Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021)

Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Kartik, Akash, et al.
Publicado: (2023)

Rebound hypothermia after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and cardiac arrest in immediate postoperative period: a report of two cases and review of literature
por: Solanki, Sohan Lal, et al.
Publicado: (2020)

Anesthetic management of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): The importance of hydro-electrolytic and acid-basic control
por: Mendonça, Fabrício Tavares, et al.
Publicado: (2017)

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
por: Zhang, Guyu, et al.
Publicado: (2019)

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
por: Harper, Megan M., et al.
Publicado: (2022)

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review
por: Chen, Vicky, et al.
Publicado: (2022)

Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix
por: Kaakour, Dalia, et al.
Publicado: (2023)

Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
por: Zhou, Sicheng, et al.
Publicado: (2021)

Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)
por: Manzanedo, Israel, et al.
Publicado: (2023)

Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups
por: Gomes David, Manuel, et al.
Publicado: (2022)

Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review
por: Noiret, Barbara, et al.
Publicado: (2022)

Perioperative anaesthetic management in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a retrospective analysis in a single tertiary care cancer centre
por: Gupta, Raghav, et al.
Publicado: (2022)

Late Recurrence of Pancreatic Solid Pseudopapillary Neoplasm With Peritoneal Carcinomatosis Treated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Case Report
por: Nogueiro, Jorge, et al.
Publicado: (2022)

A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer
por: BATISTA, THALES PAULO, et al.
Publicado: (2022)

Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
por: Munoz-Zuluaga, Carlos A., et al.
Publicado: (2020)

Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts
por: Herold, Zoltan, et al.
Publicado: (2022)

The Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) versus Conventional Surgery on Patient-Reported Outcomes: A Comparative Cohort Study between the CAIRO6 Trial and the PROCORE Study
por: Bakkers, Checca, et al.
Publicado: (2023)

Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial
por: Qi, Yuwen, et al.
Publicado: (2022)

Etiological analysis of infection after CRS + HIPEC in patients with PMP
por: Yang, Rui, et al.
Publicado: (2023)

Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study
por: Hentzen, Judith E. K. R., et al.
Publicado: (2019)

Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
por: Acs, Miklos, et al.
Publicado: (2022)

P.R.O.P.S. — A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Yong, Zachary Zihui, et al.
Publicado: (2019)

Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
por: Kleber, Julia, et al.
Publicado: (2023)

Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
por: Roth, Lilian, et al.
Publicado: (2023)

Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
por: Acs, Miklos, et al.
Publicado: (2023)

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes
por: Marrelli, Daniele, et al.
Publicado: (2022)

Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Jayakrishnan, Thejus T, et al.
Publicado: (2014)

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer
por: Wang, Xiao, et al.
Publicado: (2020)

Pharmacological Prophylaxis and Personal Protective Equipment (PPE) Practices in Gynecological Cancer Surgery During COVID-19 Pandemic
por: Singh, Pooja, et al.
Publicado: (2021)

Pre-Anesthesia Re-Evaluation in Post COVID-19 Patients Posted for Elective Surgeries: an Online, Cross-Sectional Survey.
por: Wajekar, Anjana S, et al.
Publicado: (2021)

Complex and Challenging Surgery like CRS with HIPEC is Easible Midst the COVID 19 Pandemic: Experience from Tertiary Care Center in India
por: Ray, M. D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ls3pno9k433hn8ou360uols3gt